MRS2 and endometrial cancer: A 5-biomarker panel of cervico-vaginal fluid derived proteins (HPT, LG3BP, FGA, LY6D and IGHM) predicted endometrial cancer with an AUC of 0.95 (0.91–0.98), sensitivity of 91% (83%–98%), and specificity of 86% (78%–95%).